BridgeBio Pharma
BridgeBio Pharma's revenue rose 126.3% to $502 million in fiscal 2025. Its operating margin was −104.2%, up from −267.2% a year earlier. Free cash flow was −$447 million. It paid out $48 million in dividends and buybacks. The diluted share count rose 2.9%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What BridgeBio Pharma does
BridgeBio Pharma is a drug company that develops medicines for genetic diseases. It says more than 8,500 patients have been treated with its approved medicines, and the FDA has approved three of its products. Its largest product is acoramidis, approved in November 2024 for a heart condition called transthyretin amyloid cardiomyopathy and sold in the United States as Attruby.
Outside the United States acoramidis is sold as Beyonttra, through partners such as Bayer in Europe and Alexion in Japan, and directly by BridgeBio in some other markets. It earns money from its product sales and works with partners abroad. It runs a decentralized "hub and spoke" model, with a separate team for each program in its portfolio.
It plans to seek approval for several late-stage candidates, including treatments for achondroplasia, limb-girdle muscular dystrophy type 2I/R9, and autosomal dominant hypocalcemia type 1, which have all released positive Phase 3 data.
Its biggest risks, as it describes them
- Its dependence on the commercial success of Attruby and Beyonttra.
- Delays or setbacks in clinical trials, including difficulty enrolling patients.
- Efforts to lower drug prices, such as reference pricing and most-favored-nation models.
- Penalties if it fails to follow healthcare laws and government drug pricing program rules.
- Smaller markets for its drug candidates than it expects.
Income statement
BridgeBio Pharma lost money in fiscal 2025: a net loss of $733 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 788 | 428 | 376 | 681 | 588 |
| Debt incl. finance leases | 432 | 431 | 446 | 437 | 2,007 |
| Net debt (negative means net cash) | −355 | 3 | 70 | −244 | 1,420 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | −12.3x | −6.4x | −7.5x | −6.5x | −9.9x |
| Current ratio | 6.6x | 4.5x | 3.3x | 4.7x | 2.8x |
| Quick ratio | 6.6x | 4.5x | 3.3x | 4.7x | 2.7x |
Cash flow
Projections
Project BridgeBio Pharma's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought BridgeBio Pharma shares on the open market, and 7 insiders sold $86.2 million, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | Neil KumarChief Executive Officer, Director | Sold plan | 10,000 | $69.08 | $690,816 | Form 4 |
| Aug 19, 2026 | Neil KumarChief Executive Officer, Director | Sold plan | 10,000 | $84.03 | $840,273 | Form 4 |
| Aug 18, 2026 | Neil KumarChief Executive Officer, Director | Sold plan | 34,980 | $82.53 | $2.9 million | Form 4 |
| Jul 30, 2026 | Maricel ApuliChief Accounting Officer | Sold plan | 2,000 | $80.06 | $160,120 | Form 4 |
| Jul 9, 2026 | Jennifer E. CookDirector | Sold plan | 148,589 | $88.54 | $13.2 million | Form 4 |
| Jul 9, 2026 | Andrea EllisDirector | Sold plan | 17,167 | $84.00 | $1.4 million | Form 4 |
| Jun 24, 2026 | Jennifer E. CookDirector | Sold plan | 37,167 | $70.00 | $2.6 million | Form 4 |
| Jun 23, 2026 | Hannah ValantineDirector | Sold plan | 2,196 | $68.57 | $150,580 | Form 4 |
| Jun 22, 2026 | Hannah ValantineDirector | Sold plan | 2,808 | $68.00 | $190,944 | Form 4 |
| Jun 15, 2026 | Jennifer E. CookDirector | Sold plan | 90,240 | $66.63 | $6.0 million | Form 4 |
| Jun 5, 2026 | Neil KumarChief Executive Officer, Director | Sold plan | 40,000 | $67.88 | $2.7 million | Form 4 |
| Jun 4, 2026 | Neil KumarChief Executive Officer, Director | Sold plan | 40,000 | $67.46 | $2.7 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 1 of 9 | 6 of 9 | 3 of 9 |
| Rule of 40 | −5,774.6% | 2,050.2% | 37.2% |
| Altman Z'' | −19.49 | −11.92 | −14.22 |
| Accruals ratio | −21.5% | −3.1% | −30.9% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Fail |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 1 of 9 | 6 of 9 | 3 of 9 |
Compare
Put BridgeBio Pharma side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| BridgeBio Pharma | FY25 | 126.3% | −104.2% | −89.0% | — | — | 3 | |
| Travere Therapeutics | FY25 | 110.5% | −12.8% | — | — | — | 7 | Compare |
| Mirum Pharmaceuticals | FY25 | 54.7% | −4.2% | 10.5% | −7.1% | −34.9x | 5 | Compare |
| Zai Lab | FY25 | 15.3% | −49.9% | −34.5% | — | — | — | Compare |
| HUTCHMED (China) | FY25 | −13.0% | −7.1% | −14.4% | — | — | 4 | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | — | — | 41 | 8 | 70 | 78 | 9 | 222 | 502 |
| Revenue growth | — | — | — | −79.7% | 745.1% | 11.4% | −88.0% | 2,285.3% | 126.3% |
| Gross profit | — | — | — | — | 67 | 74 | 7 | 218 | 481 |
| Research and development | 31 | 140 | 210 | 337 | 451 | 400 | 456 | 506 | 452 |
| Operating income | −44 | −184 | −266 | −474 | −577 | −512 | −607 | −593 | −523 |
| Net income | −44 | −170 | −289 | −506 | −586 | −485 | −653 | −543 | −733 |
| Diluted EPS (US$) | −1.00 | −2.12 | −2.48 | −3.80 | −3.90 | −3.26 | −3.95 | −2.88 | −3.78 |
| Diluted shares (millions) | 31 | 62 | 105 | 118 | 144 | 148 | 163 | 186 | 192 |
| Cash flow | |||||||||
| Cash from operations | −40 | −137 | −254 | −400 | −498 | −420 | −528 | −521 | −446 |
| Capital expenditure | 0 | 2 | 3 | 8 | 13 | 5 | 1 | 1 | 1 |
| Free cash flow | −41 | −139 | −256 | −407 | −511 | −424 | −529 | −522 | −447 |
| Dividends paid | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 75 | 200 | 0 | 0 | 0 | 48 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 6 | 21 | 58 | 100 | 92 | 109 | 96 | 133 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 92 | 436 | 546 | 607 | 788 | 428 | 376 | 681 | 588 |
| Debt incl. finance leases | — | 54 | 95 | 96 | 432 | 431 | 446 | 437 | 2,007 |
| Total assets | — | 465 | 632 | 704 | 1,013 | 623 | 546 | 919 | 936 |
| Total liabilities | — | 88 | 156 | 596 | 1,878 | 1,868 | 1,889 | 2,377 | 3,013 |
| Shareholders' equity | 86 | 315 | 408 | 58 | −870 | −1,255 | −1,354 | −1,468 | −2,087 |
| Margins and ratios | |||||||||
| Gross margin | — | — | — | — | 95.5% | 95.6% | 73.7% | 98.2% | 95.8% |
| Operating margin | — | — | −656.4% | −5,752.0% | −827.1% | −659.6% | −6,528.8% | −267.2% | −104.2% |
| Net margin | — | — | −711.5% | −6,127.9% | −841.2% | −624.2% | −7,021.9% | −244.9% | −146.0% |
| Free cash flow margin | — | — | −631.7% | −4,936.7% | −733.2% | −546.5% | −5,686.6% | −235.1% | −89.0% |
| Rule of 40 (growth + FCF margin) | — | — | — | −5,016.4% | 11.9% | −535.1% | −5,774.6% | 2,050.2% | 37.2% |
| Return on capital | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | −79.8% | −216.8% | — | — | — | — | — |
| Return on assets | — | — | −52.6% | −75.7% | −68.3% | −59.2% | −111.7% | −74.1% | −79.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |